Physician profile
Sam V Sydney
NPI 1518961283
$129,562.83
in general payments reported to CMS, 2019-2025
16 companies · $23K in 2025
The $23K reported for 2025 was more than what 92% of Orthopaedic Surgery providers received nationally (typical 2025 total: $569).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $21K · 2020: $12K · 2021: $15K · 2022: $18K · 2023: $24K · 2024: $16K · 2025: $23K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $24K · Royalty Or License: $24K · Honoraria: $6,250 · Travel and Lodging: $5,557 · Food and Beverage: $3,196.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $24,250.00 |
| Royalty Or License | $23,968.66 |
| Honoraria | $6,250.00 |
| Travel and Lodging | $5,556.78 |
| Food and Beverage | $3,196.33 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Exactech, INC. | $82,049.13 | 2019-2024 | |
| Encore Medical, LP | $36,610.11 | 2022-2025 | Djo Surgical |
| Medical Device Business Services, INC. | $6,140.80 | 2019-2021 | |
| Supreme Orthopedic Systems, LLC | $1,857.01 | 2022-2024 | |
| Insight Medical Systems, INC. | $681.65 | 2024 | Arvis |
| Depuy Synthes Sales INC. | $483.91 | 2019-2023 | Fibulink |
| Zimmer Biomet Holdings, INC. | $459.58 | 2020-2025 | Tapestry, Activbraid |
| Stryker Corporation | $424.45 | 2019-2025 | Mako, Pangea, Blueprint Patient Specific Instrumentation |
| Medacta USA, INC. | $260.34 | 2020-2021 | |
| Arthrex, INC. | $194.95 | 2024 | |
| Ortho Development Corporation | $166.56 | 2023 | |
| Omnilife Science, INC | $84.57 | 2019 | |
| Embody, INC. | $53.82 | 2023 | |
| Pacira Pharmaceuticals Incorporated | $40.50 | 2023 | Iovera, Exparel, Zilretta |
| Kinamed, INC. | $35.80 | 2019 |
Show all 16 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Heron Therapeutics, INC. | $19.65 | 2025 | Zynrelef |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
Research and ownership
$38,951.99 in ownership or investment interests, as reported to CMS. These are holdings a clinician or an immediate family member has in a company, not payments received.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Sam Sydney listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.